The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial
Open accessAbstract
Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) or matching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolic mitral annular velocities, and ratio of early mitral inflow velocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Nagueh, S. F., Middleton, K. J., Kopelen, H. A., Zoghbi, W. A., & Quiñones, M. A. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00344-6 · Cited by 3,029
Ommen, S. R., Nishimura, R. A., Appleton, C. P., Miller, F. A., Oh, J. K., Redfield, M. M., & Tajik, A. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1788 · Cited by 2,790
Vitamin D deficiency and risk of cardiovascular disease
Wang, T. J., Pencina, M. J., Booth, S. L., Jacques, P. F., Ingelsson, E., Lanier, K., Benjamin, E. J., D’Agostino, R. B., Wolf, M., & Vasan, R. S. (2008) · Circulation · doi:10.1161/circulationaha.107.706127 · Cited by 1,846
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Li, Y. C., Kong, J., Wei, M., Chen, Z.-F., Liu, S. Q., & Cao, L.-P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215219 · Cited by 1,625
Sohn, D.-W., Chai, I.-H., Lee, D.-J., Kim, H.-C., Kim, H.-S., Oh, B.-H., Lee, M.-M., Park, Y.-B., Choi, Y.-S., Seo, J.-D., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)88335-0 · Cited by 1,557
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Martin, C. J., Murray, D. C., & Barre, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.22 · Cited by 1,299
Cited by
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.04.001 · Cited by 1,956
Barbarawi, M., Kheiri, B., Zayed, Y., Barbarawi, O., Dhillon, H., Swaid, B., Yelangi, A., Sundus, S., Bachuwa, G., Alkotob, M. L., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1870 · Cited by 376
Isakova, T., Nickolas, T. L., Denburg, M., Yarlagadda, S., Weiner, D. E., Gutiérrez, O. M., Bansal, V., Rosas, S. E., Nigwekar, S., Yee, J., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.019 · Cited by 373
Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., Moe, S. M., Shroff, R., Tonelli, M. A., Toussaint, N. D., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2640 · Cited by 318
Beveridge, L. A., Struthers, A. D., Khan, F., Jorde, R., Scragg, R., Macdonald, H. M., Alvarez, J. A., Boxer, R. S., Dalbeni, A., Gepner, A. D., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0237 · Cited by 309
Metadata
- Authors
- Wang, A. Y.-M., Fang, F., Chan, J., Wen, Y.-Y., Qing, S., Chan, I. H.-S., Lo, G., Lai, K.-N., Lo, W.-K., Lam, C. W.-K., & Yu, C.-M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2014-01
- Volume
- 25
- Issue
- 1
- Pages
- 175-186
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151974901
- Cited by
- 255
- References
- 46
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. https://app.cochat.ai/papers/10.1681/asn.2013010103
- The paper
- Wang, A. Y.-M., Fang, F., Chan, J., Wen, Y.-Y., Qing, S., Chan, I. H.-S., Lo, G., Lai, K.-N., Lo, W.-K., Lam, C. W.-K., & Yu, C.-M. (2014). Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2013010103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.